代谢相关脂肪性肝病患者SAF评分和脂肪肝进展抑制算法应用研究*

doi:10.3969/j.issn.1672-5069.2025.01.013

Abstract

Abstract: Objective This study was conducted to investigate steatosis-activity-fibrosis-based SAF score and fatty liver inhibition of progression (FLIP) algorithm in evaluation of liver fibrosis in patients with metabolic associated fatty liver disease (MAFLD). Methods This study recruited 113 individuals with MAFLD in our hospital between August 2020 and March 2021, and all underwent liver biopsies. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) were detected by FibroScan. Compensated progressive chronic liver disease (cACLD) was determined by Baveno VII consensus. Results Of 113 patients with MAFLD, liver histo-pathological examination showed F0-F2 liver fibrosis (non-cACLD) in 91 cases and F3-F4(cACLD) in 22 cases; there were significant differences as respect to percentages of concomitant type 2 diabetes, etiologies and alcohol intake between patients with and without cACLD (P<0.05); CAP and LSM in patients with cACLD were 247.5(230.0-301.5) dB/m and (22.0±16.2)kPa, much different as compared to [299.0(260.2-325.2)dB/m and (9.6±4.4)kPa] in non-cACLD (P<0.05); platelet count, total serum bilirubin, uric acid and LDL-C levels in cACLD were all significantly different compared to in non-cACLD (P<0.05); SAF score in cACLD was(8.4±1.1), much higher than [(5.7±1.8), P<0.05] in non-cACLD; FLIP algorithm found nonalcoholic steatohepatitis (NASH) accounted for 86.4% and no fatty liver disease for 13.6% in cACLD, while found NASH for 40.7%, nonalcoholic simple fatty liver for 53.8% and no fatty liver disease for 5.5% in non-cACLD. Conclusion MAFLD could include multiple etiologies, SAF score could diagnose cACLD and FLIP algorithm could help screen existence of NASH, which warrants further clinical investigation.

Key words: Metabolic associated fatty liver disease, SAF score, Fatty liver inhibition of progression, Compensated advanced chronic liver disease, Diagnosis

Huang Jiawei, Ji Yali, Zhou Ling, et al. SAF score and fatty liver inhibition of progression algorithm in evaluation of liver fibrosis in patients with metabolic associated fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(1): 48-51.

References

[1] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020,73(1): 202-209.
[2] Khalifa A, Rockey DC. The utility of liver biopsy in 2020. Curr Opin Gastroenterol, 2020,36(3): 184-191.
[3] Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology, 2012,56(5): 1751-1759.
[4] Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology, 2014,60(2): 565-575.
[5] Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol, 2020,72(5): 828-838.
[6] Hagstrom H, Nasr P, Ekstedt M, et al. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scand J Gastroenterol, 2017,52(1): 87-91.
[7] Kumar R, Mohan S. Non-alcoholic fatty liver disease in lean subjects: Characteristics and implications. J Clin Transl Hepatol, 2017,5(3): 216-223.
[8] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004,27(6): 1487-1495.
[9] de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015,63(3): 743-752.
[10] Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology, 2012,56(5): 1751-1759.
[11] 肖亮. 肝脏穿刺活检湘雅专家共识. 中国普通外科杂志, 2021,30(1):1-8.
[12] Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol, 2015,62(Suppl 1): S47-S64.
[13] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023,78(6): 1966-1986.
[14] Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int, 2023,17(4): 773-791.
[15] Estes C, Chan H, Chien RN, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther, 2020,51(8): 801-811.
[16] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021,397(10290): 2212-2224.
[17] Lin H, Zhang X, Li G, et al. Epidemiology and clinical outcomes of metabolic (dysfunction)-associated fatty liver disease. J Clin Transl Hepatol, 2021,9(6): 972-982.
[18] 杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查. 实用肝脏病杂志, 2022,25(2):153-156.
[19] Chen Y, Fan C, Chen Y, et al. Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study. Oncotarget, 2017,8(35): 58601-58610.
[20] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol, 2021,18(3): 151-166.

SAF score and fatty liver inhibition of progression algorithm in evaluation of liver fibrosis in patients with metabolic associated fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Su Ya, Wang Bingyuan. Alcoholic liver disease is not metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 5-8.
[2]	Wang Changhe, Zhu Xuan, Deng Jing, et al. Preliminary diagnosis of liver fibrosis by shear wave elastography in combination with AAR, APRI and FIB-4 in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2025, 28(1): 32-35.
[3]	Hu Yu, Wang Jinghui, Wang Yao. Combination of sound palpation tissue quantification and FIB-4 index and AST/ALT ratio in evaluation of liver fibrosis in patients with hepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 36-39.
[4]	Ma Min, Xu Qiaoyun. Clinical implications of serum arginase-1 levels and apolipoprotein B /apolipoprotein A1 ratio in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 52-55.
[5]	Shen Yue, Zhu Ning, Wang Hai. Diagnostic performance of FibroTouch parameters in the diagnosis of non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 60-63.
[6]	Yang Huiling, Zhao Wenzhe, Yang Liuqing, et al. DCE-MRI functional imaging parameters in the diagnosis of decompensated liver functions in patients with hepatitis B-related liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 92-95.
[7]	Si Tong, Zhu Jiabao, Wu Binbin. Ultrasonography and shear wave elastography in predicting high risk esophageal varices in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 100-103.
[8]	Jiang Shetian, Yan Wei, Zhao Lei, et al. Diagnostic performance of ultrasound virtual touch tissue quantification and serum liver fibrosis markers in predicting liver fibrosis in patients with hepatic schistosomiasis [J]. Journal of Practical Hepatology, 2025, 28(1): 124-127.
[9]	Fu Lin, Zhang Lingyin, Wei Qian. Application of MRI in qualitative diagnosis of focal nodular lesions of liver in patients with NAFLD [J]. Journal of Practical Hepatology, 2025, 28(1): 140-143.
[10]	Zhou Jun, Zhang Zhongxin, Xu Haiyan. Assessment of significant liver fibrosis by visual instantaneous elastography and acoustic palpation elastography in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(6): 832-835.
[11]	Wu Yu, Han Yuxing, Xu Manman, et al. Hospital profit and deficit of medical costs in patients with acute-on-chronic liver failure based on DRG payment reform [J]. Journal of Practical Hepatology, 2024, 27(6): 882-886.
[12]	Tang Min, Zeng Li, Yang Xinrong. FibroTouch and virtual touch tissue quantification parameters in evaluating liver fibrosis in patients with schistosomiasis-induced liver disease [J]. Journal of Practical Hepatology, 2024, 27(6): 887-890.
[13]	Chen Siyan, Guo Daoning, Zou Xiaopan, et al. Assessment of stent function by color Doppler ultrasonography in patients with liver cirrhosis and portal hypertension after transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2024, 27(6): 899-902.
[14]	Zeng Wang, Cai Xiaoman, Ge Shang. Enhanced MRI manifestation feature in differential diagnosis of ICC and HCC: A single center study [J]. Journal of Practical Hepatology, 2024, 27(6): 907-910.
[15]	Danba Yuzhen, Cheng Pan. Gd-EOB-DTPA-enhanced MRI scan in diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 911-914.